NASDAQ:DNLI - Denali Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $79.88
  • Forecasted Upside: 152.13 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$31.68
▲ +0.44 (1.41%)

This chart shows the closing price for DNLI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Denali Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DNLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DNLI

Analyst Price Target is $79.88
▲ +152.13% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $79.88, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 152.13% upside from the last price of $31.68.

This chart shows the closing price for DNLI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Denali Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/23/2022Berenberg BankInitiated CoverageBuy$39.00Low
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$99.00 ➝ $82.00Low
5/6/2022WedbushLower Price Target$62.00 ➝ $48.00High
3/7/2022The Goldman Sachs GroupLower Price TargetBuy ➝ Buy$114.00 ➝ $98.00High
3/1/2022WedbushReiterated RatingOutperformMedium
1/6/2022Morgan StanleyLower Price TargetOverweight$99.00 ➝ $91.00Low
11/5/2021Evercore ISIBoost Price TargetOutperform$70.00 ➝ $111.00High
9/20/2021OppenheimerInitiated CoverageOutperform$85.00High
9/1/2021Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$78.00High
8/16/2021Morgan StanleyLower Price TargetOverweight$100.00 ➝ $99.00Medium
7/26/2021HC WainwrightReiterated RatingBuy$95.00 ➝ $105.00High
7/15/2021HC WainwrightReiterated RatingBuy$95.00Medium
5/18/2021UBS GroupInitiated CoverageBuy$70.00High
3/4/2021HC WainwrightBoost Price TargetBuy$80.00 ➝ $95.00High
2/26/2021HC WainwrightReiterated RatingBuy$80.00 ➝ $95.00High
2/10/2021Cantor FitzgeraldUpgradeNeutral ➝ Overweight$105.00Low
1/8/2021JPMorgan Chase & Co.Initiated CoveragePositiveMedium
12/16/2020Morgan StanleyBoost Price TargetOverweight$75.00 ➝ $100.00High
11/11/2020JPMorgan Chase & Co.Boost Price TargetPositive ➝ Overweight$45.00 ➝ $65.00High
11/11/2020Morgan StanleyBoost Price TargetOverweight$45.00 ➝ $75.00High
11/10/2020The Goldman Sachs GroupBoost Price TargetPositive ➝ Buy$61.00 ➝ $81.00Low
11/6/2020HC WainwrightBoost Price TargetBuy$45.00 ➝ $65.00Medium
10/16/2020WedbushBoost Price TargetPositive ➝ Outperform$39.00 ➝ $50.00High
10/16/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$35.00High
8/24/2020Morgan StanleyBoost Price TargetOverweight$28.00 ➝ $45.00Medium
8/20/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $45.00Medium
8/10/2020WedbushReiterated RatingOutperformMedium
5/13/2020NomuraReiterated RatingBuy$35.00Low
4/15/2020Morgan StanleyLower Price TargetOverweight$30.00 ➝ $28.00High
3/18/2020Cantor FitzgeraldReiterated RatingNeutralMedium
3/13/2020Evercore ISIUpgradeIn-Line ➝ Outperform$20.00High
3/9/2020Nomura SecuritiesReiterated RatingBuy$35.00Low
2/28/2020WedbushUpgradeNeutral ➝ Outperform$24.00Low
2/24/2020Jefferies Financial GroupInitiated CoverageBuy$35.00High
2/18/2020Stifel NicolausInitiated CoverageHold$26.00Low
1/26/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$20.00 ➝ $37.00High
12/20/2019HC WainwrightReiterated RatingBuy$28.00Medium
9/25/2019WedbushInitiated CoverageNeutral$19.00 ➝ $19.00High
9/13/2019Nomura SecuritiesInitiated CoverageBuy$35.00High
8/9/2019Morgan StanleySet Price TargetBuy$32.00Low
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$30.00High
8/8/2019HC WainwrightReiterated RatingBuyMedium
7/15/2019HC WainwrightSet Price TargetBuy$28.00High
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$28.00Medium
1/29/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$25.00High
12/7/2018Cantor FitzgeraldReiterated RatingBuy$25.00High
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$25.00High
11/12/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$26.00Low
1/2/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$23.00Medium
1/2/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ NeutralHigh
1/2/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$25.00High
1/2/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$24.00High
(Data available from 7/6/2017 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/7/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/6/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/8/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/7/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/6/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/6/2022

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Denali Therapeutics logo
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $31.68
Low: $29.44
High: $31.71

50 Day Range

MA: $24.97
Low: $20.88
High: $31.24

52 Week Range

Now: $31.68
Low: $20.24
High: $78.89

Volume

711,143 shs

Average Volume

601,161 shs

Market Capitalization

$3.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Denali Therapeutics?

The following equities research analysts have issued stock ratings on Denali Therapeutics in the last year: Berenberg Bank, Evercore ISI, HC Wainwright, Morgan Stanley, Oppenheimer Holdings Inc., Sumitomo Mitsui Financial Group, Inc., The Goldman Sachs Group, Inc., TheStreet, and Wedbush.
View the latest analyst ratings for DNLI.

What is the current price target for Denali Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Denali Therapeutics in the last year. Their average twelve-month price target is $79.88, suggesting a possible upside of 152.1%.
View the latest price targets for DNLI.

What is the current consensus analyst rating for Denali Therapeutics?

Denali Therapeutics currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DNLI will outperform the market and that investors should add to their positions of Denali Therapeutics.
View the latest ratings for DNLI.

How do I contact Denali Therapeutics' investor relations team?

Denali Therapeutics' physical mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (615) 866-8548 and its investor relations email address is [email protected] The official website for Denali Therapeutics is www.denalitherapeutics.com. Learn More about contacing Denali Therapeutics investor relations.